Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Journal of Endocrinology

Volumn 169, Issue 1, 2001, Pages 65-70

  Charmandari, E ^a   Johnston, A ^a   Brook, C G D ^a   Hindmarsh, P C ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; STEROID 21 MONOOXYGENASE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; EVALUATION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MEASUREMENT; PEDIATRICS; PRIORITY JOURNAL; STATISTICS; STEROID 21 MONOOXYGENASE DEFICIENCY; TABLET; TECHNIQUE; TIME;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHILD; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE; TIME FACTORS;

EID: 0035068588     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1690065     Document Type: Article

References (22)

1. Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man
2. Clearance
3. Bioavailability and first-pass clearance
4. Designing dose regimens
5. Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate
6. Pharmacokinetics and oral bioavailability of hydrocortisone
7. Plasma cortisol delivery from oral cortisol and cortisone acetate: Relative bioavailability
8. The role of adrenal in generating the diurnal variation in circulating levels of corticosteroid-binding globulin in the rat
9. Basal ACTH, corticosterone and corticosterone-binding globulin levels over the diurnal cycle, and age-related changes in hippocampal type I and type II corticosteroid receptor binding capacity in young and aged, non-handled rats
10. Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses
11. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: In vivo and in vitro studies
12. Bioequivalence requirements for generic products
13. Bioavailability of hydrocortisone from commercial 20-mg tablets
14. Hepatic clearance and elimination
15. Intravenous dose
16. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
17. Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression
18. Sexual dimorphism in 11β-hydroxysteroid dehydrogenase activity and its relation to fat distribution and insulin sensitivity: A study in hypopituitary subjects
19. The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood